Trial Profile
A single center, open-label, randomized, two-period, crossover, single-dose study to determine the effect of food on the bioavailability of fixed combination SPA100 (aliskiren/amlodipine 300/10 mg oral tablets) in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Sep 2016
Price :
$35
*
At a glance
- Drugs Aliskiren/amlodipine (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Novartis
- 11 Feb 2010 New trial record